Document is current
Any future updates will be listed below
-
Authors
Grillo, Sara https://orcid.org/0000-0002-3596-8690
Pujol, Miquel https://orcid.org/0000-0002-6475-6208
Miró, Josep M.
López-Contreras, Joaquín https://orcid.org/0000-0002-3166-4016
Euba, Gorane
Gasch, Oriol
Boix-Palop, Lucia https://orcid.org/0000-0002-4080-0008
Garcia-País, Maria José
Pérez-Rodríguez, Maria Teresa
Gomez-Zorrilla, Silvia
Oriol, Isabel
López-Cortés, Luis Eduardo
Pedro-Botet, Maria Luisa
San-Juan, Rafael https://orcid.org/0000-0003-3446-1991
Aguado, José María
Gioia, Francesca
Iftimie, Simona
Morata, Laura
Jover-Sáenz, Alfredo
García-Pardo, Graciano
Loeches, Belén
Izquierdo-Cárdenas, Álvaro
Goikoetxea, Ane Josune
Gomila-Grange, Aina
Dietl, Beatriz
Berbel, Damaris
Videla, Sebastian https://orcid.org/0000-0001-5049-1379
Hereu, Pilar
Padullés, Ariadna
Pallarès, Natalia
Tebé, Cristian
Cuervo, Guillermo
Carratalà, Jordi https://orcid.org/0000-0003-3209-2563
,
Rivera, Maria Alba
Aguirregabiria, Malen
Rodríguez-Álvarez, Regino
Blanco-Vidal, María José
Alguacil-Guillen, Marina
Xercavins, Mariona
Pomar, Virginia
Siverio-Parés, Ana
de Cueto, Marina
Moreno-Mellado, Elisa
Sousa, Adrián
Vasallo-Vidal, Francisco José
Borjabad, Beatriz
Coloma-Conde, Ana
Clivillé-Abad, Raquel
González-di Lauro, Sabina Ximena
Tiago-Silva, Jose
Orellana, Maria Angeles
Ruíz-Bastián, Mario
Vizcarra, Pilar
Garcia, Carles
Ballester, Frédéric
Ramírez-Hidalgo, María Fernanda
Bellés-Bellés, Alba
Meije, Yolanda
Ribera, Alba
LLaberia, Jaume
Domínguez, María Ángeles
Rigo-Bonnin, Raul Francisco
Horna, Gertrudis
Mediavilla, Dominica
Sanllorente, Mireia
Picó-Plana, Ester
Soriano, Alex
Pitart, Cristina
Sanchez-Diaz, Ana Maria
- License Information
-
More Information
Article History
Received: 27 April 2023
Accepted: 25 August 2023
First Online: 2 October 2023
Competing interests
: M.P. received a research grant from Laboratorios ERN. J.M.M. has received consulting honoraria and/or research grants from Angelini Pharma, ContraFect, Genentech, Gilead Sciences, Janssen, Lysovant, Medtronic, Merck Sharp & Dohme (MSD), Novartis, Pfizer and ViiV Healthcare, outside the submitted work. J.L.C. has received speaker honoraria from Pfizer, MSD, AstraZeneca, Guerbet and Hartmann. L.E.L.C. has served as scientific advisor for Angelini Pharma, speaker for Angelini Pharma, ViiV Healthcare, Gilead Sciences and Correvio, and trainer for ViiV Healthcare. J.M.A. has received honoraria for speaking at symposia organised on behalf of Pfizer, Astellas, MSD, Angelini Pharma, Shionogi, Takeda and Gilead Sciences, and has sat on advisory boards on behalf of Pfizer, Astellas, MSD, Angelini Pharma, Gilead Sciences and Takeda. Á.I.C. has received speaker honoraria from Pfizer, Bristol Myers Squibb, Esteve and Bayer. C.T. has received speaker honoraria from Gedeon Richter. G.C. has received support for attending national and international scientific congresses from Angelini Pharma Spain, Pfizer Spain and MSD, and speaker honoraria from Pfizer Spain and Gilead Sciences Europe. J.C. has received speaker honoraria from MSD and Gilead Sciences, and has participated as an investigator in trials on COVID-19 by Roche and Gilead Sciences. The rest of the authors do not declare any conflicts of interest.
